BUPRENORPHINE ENZYME IMMUNOASSAY, CALIBRATORS AND CONTROLS FOR BECKMAN COULTER SYNCHRON SYSTEMS

K081008 · Lin-Zhi International, Inc. · DJG · Dec 22, 2008 · Clinical Toxicology

Device Facts

• Record ID: K081008
• Device Name: BUPRENORPHINE ENZYME IMMUNOASSAY, CALIBRATORS AND CONTROLS FOR BECKMAN COULTER SYNCHRON SYSTEMS
• Applicant: Lin-Zhi International, Inc.
• Product Code: DJG · Clinical Toxicology
• Decision Date: Dec 22, 2008
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3650
• Device Class: Class 2

Indications for Use

The Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay, when used in conjunction with Beckman Coulter® Synchron LX®, CX®, and UniCel® DxC automated clinical system analyzers, is intended for the qualitative and semi-quantitative determination of norbuprenorphine (buprenorphine metabolite) in human urine, at a cutoff value of 10 ng/mL. The Norbuprenorphine Drugs of Abuse (DAU) Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay with Beckman Coulter® Synchron LX®, CX®, and UniCel® DxC automated clinical system analyzers. The Norbuprenorphine Drugs of Abuse (DAU) Controls are for use as assayed quality control materials to monitor the precision of the Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay with Beckman Coulter® Synchron LX®, CX®, and UniCel® DxC automated clinical system analyzers. The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Chromatography/mass spectrometry (GC/MS or LC/MS) is the preferred confirmatory method (1,2). Clinical consideration and professional judgement should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

Device Story

Homogeneous enzyme immunoassay for norbuprenorphine detection in human urine; utilizes competitive binding between sample drug and enzyme-labeled drug (G6PDH) for fixed antibody sites. In absence of drug, antibody inhibits enzyme; in presence of drug, enzyme remains active, converting NAD to NADH. Measured spectrophotometrically at 340 nm. Used in clinical laboratories on Beckman Coulter automated chemistry analyzers. Provides preliminary qualitative/semi-quantitative results; requires GC/MS confirmation. Assists clinicians in identifying buprenorphine metabolite presence for drug abuse screening.

Clinical Evidence

Bench testing only. Precision evaluated via intra-assay and between-run studies across three analyzer platforms (CX4CE, LX20 Pro, DxC 600) using spiked urine samples. Linearity confirmed via serial dilution (recovery within +/- 15%). Analytical specificity tested against common interfering substances and specific gravity variations. Method comparison performed against GC/MS reference method, showing high percent agreement (93-97.5% depending on analyzer). No clinical patient studies performed.

Technological Characteristics

Homogeneous enzyme immunoassay; G6PDH enzyme label; spectrophotometric detection at 340 nm. Liquid, ready-to-use reagents. Analyzers: Beckman Coulter Synchron LX, CX, and UniCel DxC. Storage: 2-8°C. Qualitative and semi-quantitative modes.

Indications for Use

Indicated for the qualitative and semi-quantitative determination of norbuprenorphine (buprenorphine metabolite) in human urine for individuals undergoing drug screening. Intended for use by clinical laboratories on automated analyzers. Provides preliminary results only; requires confirmation by GC/MS or LC/MS.

Regulatory Classification

Identification

An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• CEDIA® Buprenorphine Assay (K040316)

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k081008

B. Purpose for Submission:
New device

C. Measurand:
Norbuprenorphine

D. Type of Test:
Qualitative and semi-quantitative Homogenous Enzyme Immunoassay

E. Applicant:
Lin-Zhi International, Inc.

F. Proprietary and Established Names:
Buprenorphine Enzyme Immunoassay
Norbuprenorphine Drugs of Abuse (DAU) Calibrators
Norbuprenorphine Drugs of Abuse (DAU) Controls

G. Regulatory Information:

| Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| DJG | Class II | 21 CFR 862.3650- Opiate Test System | 91-Toxicology |
| DLJ | Class II | 21 CFR 862.3200 – Clinical Toxicology Calibrators | 91-Toxicology |
| LAS | Class I | 21 CFR 862.3280 – Clinical Toxicology control material | 91- Toxicology |

{1}

H. Intended Use:

1. Intended use(s):

See indications for use below

2. Indication(s) for use:

The Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay when used in conjunction with Beckman Coulter Synchron LX, CX and UniCel DxC automated clinical chemistry analyzers, is intended for the qualitative and semi-quantitative determination of norbuprenorphine (buprenorphine metabolite) in human urine, at a cutoff value of 10 ng/mL.

The Norbuprenorphine Drugs of Abuse (DAU) Calibrators are for use as calibrators in qualitative and semi-quantitative calibration of the Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay with Beckman Coulter Synchron LX, CX and UniCel DxC automated clinical chemistry analyzers.

The Norbuprenorphine Drugs of Abuse (DAU) Controls are for use as assayed quality control materials to monitor the precision of the Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay with Beckman Coulter Synchron LX, CX and UniCel DxC automated clinical chemistry analyzers.

The assay provides a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when the preliminary result is positive.

3. Special conditions for use statement(s):

The assay is for prescription use.

4. Special instrument requirements:

Beckman Coulter Synchron CX, LX and UniCel DxC automated clinical chemistry analyzers.

I. Device Description:

The assay consists of ready-to-use liquid reagents. Reagent 1 contains mouse monoclonal anti-buprenorphine antibody, glucose-6-phosphate (G6P), nicotinamide adenine dinucleotide (NAD) and stabilizers. Reagent 2 contains buprenorphine-labeled glucose-6-phosphate dehydrogenase (G6PDH) in buffer. The calibrators controls are ready to use human urine-based liquid and are sold separately.

{2}

3

J. Substantial Equivalence Information:

1. Predicate device name(s):
CEDIA Buprenorphine Assay, Microgenics Corporation

2. Predicate 510(k) number(s):
k040316

3. Comparison with predicate:

| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Intended Use | The assay is intended for the qualitative and semi-quantitative determination of norbuprenorphine (buprenorphine metabolite) in human urine. | The assay is for detecting the presence of Buprenorphine in human urine. |
| Ready to use | Yes | Yes |
| Determination mode | Qualitative and semi-quantitative | Qualitative and semi-quantitative |
| Matrix | Urine | Urine |
| Storage | 2-8°C until expiration date | 2-8°C until expiration date |
| Differences | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Metabolite cross-reactants | Norbuprenorphine | Buprenorphine-3-β-D glucuronide |
| Calibrators level | 6 levels (0, 5, 10, 20, 40 and 100 ng/ml) | 5 levels (0, 5, 20, 50 and 75 ng/ml) |
| Cutoff | 10 ng/ml | 5 ng/ml |
| Stability | 12 months at 2-8°C | 60 days at 2-8°C |
| Control Levels | 2 levels (7 and 13 ng/mL) | 2 levels (3 and 7 ng/mL) |

K. Standard/Guidance Document Referenced (if applicable):
None referenced

L. Test Principle:
The Lin-Zhi Buprenorphine assay is a homogeneous enzyme immunoassay with ready-to-use liquid reagent. The assay is based on competition between drug in the

{3}

sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. In the absence of drug in the sample, the antibody binds the conjugated buprenorphine-labeled G6PDH thus the enzyme activity is inhibited. When free drug is present on the sample, the antibody will bind to the free drug and the unbound buprenorphine-labeled G6PDH exhibits its maximal enzyme activity. The G6PDH activity is measured spectrophotometrically at 340 nm because of conversion of NAD to NADH.

## M. Performance Characteristics (if/when applicable):

### 1. Analytical performance:

#### a. Precision/Reproducibility:

Intra-assay and between run precision was determined by spiking a standard norbuprenorphine solution into drug free urine at various concentrations (-75%, -50%, -25%, at the cutoff, +25% and 50%, 75% and 100% of the cutoff). Concentrations were confirmed by LC/MS. Testing for intra-assay imprecision was performed with 21 replicates in one day on the CX4CE, LX20 Pro and DxC 600 analyzers. The between run testing was performed twice a day for 10 days on all three analyzers. The qualitative and semi-quantitative results are presented below:

Qualitative:

| Within Run | | CX4CE | LX20 Pro | DxC 600 |
| --- | --- | --- | --- | --- |
| Sample concentration (ng/mL) | No. Observations | | | |
| | | # Neg/#Pos | # Neg/#Pos | # Neg/#Pos |
| 0 (negative) | 21 | 21/0 | 21/0 | 21/0 |
| 2.5 (-75% c/o) | 21 | 21/0 | 21/0 | 21/0 |
| 5.0 (-50% c/o) | 21 | 21/0 | 21/0 | 21/0 |
| 7.5 (-25% c/o) | 21 | 21/0 | 21/0 | 21/0 |
| 10 (cutoff) | 21 | 8/13 | 0/21 | 3/18 |
| 12.5 (+25% c/o) | 21 | 0/21 | 0/21 | 0/21 |
| 15.0 (+50% c/o) | 21 | 0/21 | 0/21 | 0/21 |
| 17.5 (+50% c/o) | 21 | 0/21 | 0/21 | 0/21 |
| 20 (+100% c/o) | 21 | 0/21 | 0/21 | 0/21 |
| Between Run | | CX | LX | DxC |
| --- | --- | --- | --- | --- |
| Sample concentration (ng/mL) | No. Observations | | | |
| | | # Neg/#Pos | # Neg/#Pos | # Neg/#Pos |
| 0 (negative) | 20 | 20/0 | 20/0 | 20/0 |
| 2.5 (-75% c/o) | 20 | 20/0 | 20/0 | 20/0 |
| 5.0 (-50% c/o) | 20 | 20/0 | 20/0 | 20/0 |

{4}

| Between Run | | CX | LX | DxC |
| --- | --- | --- | --- | --- |
| 7.5 (-25% c/o) | 20 | 20/0 | 20/0 | 20/0 |
| 10 (cutoff) | 20 | 8/12 | 0/20 | 7/13 |
| 12.5 (+25% c/o) | 20 | 0/20 | 0/20 | 0/20 |
| 15.0 (+50% c/o) | 20 | 0/20 | 0/20 | 0/20 |
| 17.5 (+50% c/o) | 20 | 0/20 | 0/20 | 0/20 |
| 20 (+100% c/o) | 20 | 0/20 | 0/20 | 0/20 |

Semi-Quantitative

| Within Run | | CX4CE | LX20 Pro | DxC 600 |
| --- | --- | --- | --- | --- |
| Sample concentration (ng/mL) | No. Observations | | | |
| | | # Neg/#Pos | # Neg/#Pos | # Neg/#Pos |
| 0 (negative) | 21 | 21/0 | 21/0 | 21/0 |
| 2.5 (-75% c/o) | 21 | 21/0 | 21/0 | 21/0 |
| 5.0 (-50% c/o) | 21 | 21/0 | 21/0 | 21/0 |
| 7.5 (-25% c/o) | 21 | 21/0 | 21/0 | 21/0 |
| 10 (cutoff) | 21 | 4/17 | 0/21 | 3/18 |
| 12.5 (+25% c/o) | 21 | 0/21 | 0/21 | 0/21 |
| 15.0 (+50% c/o) | 21 | 0/21 | 0/21 | 0/21 |
| 17.5 (+50% c/o) | 21 | 0/21 | 0/21 | 0/21 |
| 20 (+100% c/o) | 21 | 0/21 | 0/21 | 0/21 |
| Between Run | | CX | LX | DxC |
| --- | --- | --- | --- | --- |
| Sample concentration (ng/mL) | No. Observations | | | |
| | | # Neg/#Pos | # Neg/#Pos | # Neg/#Pos |
| 0 (negative) | 20 | 20/0 | 20/0 | 20/0 |
| 2.5 (-75% c/o) | 20 | 20/0 | 20/0 | 20/0 |
| 5.0 (-50% c/o) | 20 | 20/0 | 20/0 | 20/0 |
| 7.5 (-25% c/o) | 20 | 20/0 | 20/0 | 20/0 |
| 10 (cutoff) | 20 | 4/16 | 4/16 | 10/10 |
| 12.5 (+25% c/o) | 20 | 0/20 | 0/20 | 0/20 |
| 15.0 (+50% c/o) | 20 | 0/20 | 0/20 | 0/20 |
| 17.5 (+50% c/o) | 20 | 0/20 | 0/20 | 0/20 |
| 20 (+100% c/o) | 20 | 0/20 | 0/20 | 0/20 |

b. Linearity/assay reportable range:

Linearity across the range was confirmed by serially diluting a spiked urine pool containing 100 ng/mL of Norbuprenorphine in 10% increments. Each sample was assayed in replicates of 10 on each analyzer in the semi-quantitative mode. The results were averaged and compared to the expected result and the percent recovery was calculated. Sponsor calculated the %

{5}

recovery by dividing the recovered result by the target concentration and then multiplying by 100. All samples except for the $40\mathrm{ng / mL}$ sample performed on the DxC 600 recovered within $\pm 15\%$ of the expected value. Results are presented below:

| Sample ng/ml | CX4CE | | | LX20 Pro | | | DxC 600 | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Expected | Observed Mean | SD | % Recovery | Mean | SD | % Recovery | Mean | SD | % Recovery |
| 5 | 5.4 | 0.1 | 108.2 | 5.4 | 0.5 | 107.4 | 5.5 | 0.3 | 109.2 |
| 10 | 10.2 | 0.3 | 102.1 | 11.0 | 0.2 | 109.8 | 10.2 | 0.4 | 102 |
| 20 | 19.6 | 0.3 | 98.0 | 20.2 | 0.5 | 101.2 | 19.9 | 0.5 | 99.6 |
| 30 | 30 | 0.6 | 99.9 | 31.6 | 0.6 | 105.5 | 31.3 | 0.9 | 104.32 |
| 40 | 42.1 | 0.9 | 105.2 | 44.5 | 2.0 | 111.2 | 46.6 | 0.8 | 116.5 |
| 50 | 53.9 | 2.6 | 107.7 | 55.7 | 2.8 | 111.3 | 56.1 | 3.4 | 112.2 |
| 60 | 67.8 | 2.7 | 113 | 64.3 | 3.0 | 107.2 | 66.5 | 4.0 | 110.9 |
| 70 | 77.5 | 2.1 | 110.7 | 79 | 8.8 | 112.8 | 73.3 | 4.4 | 104.7 |
| 80 | 83.9 | 3.7 | 104.9 | y = 1.1203x -0.9484r² =0.9978 | y = 1.0936x -0.2831r² =0.9941 | | | | |
| 90 | 91.1 | 4.4 | 101.2 | | | | | | |
| | y = 1.0605x -0.1027r²=0.9938 | | | | | | | | |

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Calibrators and Controls:

A commercially available norbuprenorphine standard solution from Cerolliant Analytical Reference Standards is used and traceable to NIST standard. This standard solution is made into a secondary (lower concentration) stock solution. The secondary stock solution is then spiked into the calibrators and controls to the desired concentration. The concentrations are confirmed by GC/MS.

Stability Studies:

Real time and accelerated studies have been conducted. Protocols and acceptance criteria were described and found to be acceptable. The manufacturer claims the following expiration date:

When stored at $2 - 8^{\circ}\mathrm{C}$ unopened product is good until expiration date which is 18 months.

On board stability is good for 14 days when stored at $2 - 8^{\circ}\mathrm{C}$ .

{6}

d. Detection limit:

Not applicable. This assay is qualitative and semi-quantitative only. Semi-quantitative values should be used to estimate concentration for dilution purposes only.

e. Analytical specificity:

Various potentially interfering substances were evaluated for potential positive/and or negative interference with the assay. Test compounds were spiked into a negative and a positive sample to various concentrations. The substances listed in the table below were determined not to interfere at the concentrations shown:

| Interfering Substance | Concentration Tested mg/dL |
| --- | --- |
| | |
| Acetone | 1000 |
| Ascorbic Acid | 400 |
| Creatinine | 500 |
| Galactose | 10 |
| r-Globulin | 500 |
| Glucose | 1500 |
| Hemoglobin | 300 |
| NaCl | 6000 |
| Oxalic Acid | 100 |
| Human Serum Albumin (HSA) | 500 |
| Urea | 2000 |
| Ethanol | 1000 |
| pH 3 | n/a |
| pH 11 | n/a |

Interference testing over the specific gravity was performed on the Cx4CE analyzer and the results are presented below:

| Specific Gravity value | Sample contains 0 ng/mL of norbuprenorphine | | Sample contains 13 ng/mL of norbuprenorphine | |
| --- | --- | --- | --- | --- |
| Sample | ng/mL | Result | ng/mL | Result |
| 1.001 | 0.0 | Negative | 12.2 | Positive |

{7}

There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false results, e.g., technical or procedural errors

Cross-reactivity was evaluated by spiking various concentrations of similarly structured drug compounds into drug-free urine. By analyzing various concentrations of each compound the sponsor determined the concentration of the drug that produced a response approximately equivalent to the $10\mathrm{ng / mL}$ cutoff concentration of the assay. The percentage cross reactivities of those compounds are presented below:

| Compound | Quantity equivalent to 10 ng/mL | % Cross-reactivity |
| --- | --- | --- |
| Buprenorphine | 10.6 | 94.5% |
| Buprenorphine-Glucuronide | 33.333 | <0.1% |
| Norbuprenorphine-Glucuronide | 1,036 | <0.1% |

f. Assay cut-off:

Analytical performance of the device around the claimed cutoff is described in precision section (1 a.) above

# 2. Comparison studies:

a. Method comparison with predicate device:

| CX4CE BUP Assay | Negative | Low Negative by GC/MS (less than -50%) or negative by Predicate | Near Cutoff Negative (between - 50% and cutoff) | Near Cutoff Positive (between cutoff and +50%) | High Positive (greater than +50%) | Percent Agreement with GC/MS |
| --- | --- | --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 3* | 8 | 32 | 93% |
| Negative | 10 | 18 | 11 | 1** | 0 | 97.5% |

{8}

*one sample contained 8.5 ng/mL Norbuprenorphine and 3.2 ng/mL buprenorphine by GC/MS, the other two samples contained 8.9 ng/mL and 9.5 ng/mL of Norbuprenorphine by GC/MS.

** sample contained 10.2 ng/mL Norbuprenorphine by GC/MS.

| LX20 Pro
BUP Assay | Negative | Low
Negative by
GC/MS (less
than -50%)
or negative
by Predicate | Near Cutoff
Negative
(between -
50% and
cutoff) | Near Cutoff
Positive
(between
cutoff and
+50%) | High
Positive
(greater
than +50%) | Percent
Agreement
with
GC/MS |
| --- | --- | --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 1* | 6 | 32 | 97.3% |
| Negative | 10 | 18 | 13 | 2** | 0 | 95.3% |

*the sample contained 8.5 ng/mL Norbuprenorphine and 3.2 ng/mL buprenorphine by GC/MS.

** the samples contained 10.2 ng/mL and 10.7 norbuprenorphine by GC/MS.

| DxC 600
BUP Assay | Negative | Low
Negative by
GC/MS (less
than -50%)
or negative
by Predicate | Near Cutoff
Negative
(between -
50% and
cutoff) | Near Cutoff
Positive
(between
cutoff and
+50%)30 | High
Positive
(greater
than +50%) | Percent
Agreement
with
GC/MS |
| --- | --- | --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 1* | 6 | 32 | 97.3% |
| Negative | 10 | 18 | 13 | 2** | 0 | 95.3% |

*the sample contained 8.5 ng/mL Norbuprenorphine and 3.2 ng/mL buprenorphine.

** the samples contained 10.2 ng/mL and 10.7 norbuprenorphine by GC/MS

b. Matrix comparison:

Not applicable test is for urine samples only

3. Clinical studies:

a. Clinical Sensitivity:

Not applicable

b. Clinical specificity:

Not applicable

c. Other clinical supportive data (when a. and b. are not applicable):

{9}

Not applicable

4. Clinical cut-off:
Not applicable

5. Expected values/Reference range:
Not applicable

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

10